Cerus (CERS) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cerus Corporation Reports Second Quarter 2016 Results
August 4, 2016 4:01 PM EDTCONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) today announced financial results for the second quarter ended June 30, 2016.
Recent developments include:
With confirmation of local Zika cases in Florida, the FDA has advised blood establishments in the affected counties to either cease local blood collections, implement pathogen reduction technology, and/or implement testing via an investigational donor screening test. The Biomedical Advanced Research and Development Authority (BARDA) awarded Cerus a 5-year contract with potential funding of up to $181 million to... More